SCHEMBL1820879

SCHEMBL1820879

CCCC(CCC)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.38
HDAC2 Q92769 3/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
ADRA1A P35348 2/20 0.38
AKR1A1 P14550 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HRH1 P35367 1/20 0.38
DRD3 P35462 1/20 0.38
SLC6A3 Q01959 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
NFKB1 P19838 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CHRM2 P08172 1/20 0.36
CHRNA4 P43681 1/20 0.36
HTR3A P46098 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19820110 0.94 CA2 (0.41) HDAC1HDAC2CHRM1CHRM3ADRA1A
SCHEMBL19962869 0.93 CA2 (0.40) HDAC1HDAC2CHRM1CHRM3ADRA1A
SCHEMBL23877035 0.92 PRKCD (0.38) HDAC1HDAC2CHRM1CHRM3ADRA1A
SCHEMBL26804670 0.91 PRKCD (0.39) SMN1; SMN2CA1CA2KMT2AGRIK1
SCHEMBL23802513 0.90 CA2 (0.43) TDP1CYP3A4TSHRNPSR1SMN1; SMN2
SCHEMBL14286264 0.88 PRKCD (0.39) SMN1; SMN2CA1CA2KMT2AGRIK1
SCHEMBL19543152 0.88 CHRM1 (0.32) HDAC1HDAC2CHRM1CHRM3ADRA1A
SCHEMBL24974748 0.87 CA2 (0.41) SMN1; SMN2CA1CA2KMT2AGRIK1
SCHEMBL19404107 0.87 CA2 (0.41) SMN1; SMN2CA1CA2KMT2AGRIK1
SCHEMBL23256441 0.87 CA2 (0.41) SMN1; SMN2CA1CA2KMT2AGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243161-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2025-07-31 US disclosed
US-12269800-B2 Delivery of therapeutic alkaloid compounds SENSORIUM THERAPEUTICS, INC. (US) 2025-04-08 US disclosed
US-20250051277-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2025-02-13 US disclosed
US-20240246910-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2024-07-25 US disclosed
US-11999694-B2 Delivery of therapeutic alkaloid compounds SENSORIUM THERAPEUTICS, INC. (US) 2024-06-04 US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
WO-2023076586-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2023076586-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
EP-1311242-A4 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS NEW RIVER PHARMACEUTICALS INC (US) 2005-09-28 EP disclosed
CN-1649614-A Active agent delivery systems and methods for protecting and administering active agents NEW RIVER PARMACEUTICALS INC (US) 2005-08-03 CN disclosed
EP-1490090-A2 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS New River Pharmaceuticals Inc. (US) 2004-12-29 EP disclosed
US-20040063628-A1 Active agent delivery systems and methods for protecting and administering active agents NEW RIVER PHARMACEUTICALS INC. 2004-04-01 US disclosed
CN-1476325-A Delivery system for active substances and method for protecting and administering active substances 新河药品股份有限公司 2004-02-18 CN disclosed
WO-2003101476-A1 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS NEW RIVER PHARMACEUTICALS INC. (US) 2003-12-11 WO disclosed
WO-2003079972-A2 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS NEW RIVER PARMACEUTICALS INC. (US) 2003-10-02 WO disclosed
EP-1311242-A1 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS New River Pharmaceuticals, Inc. (US) 2003-05-21 EP disclosed
US-20020099013-A1 Active agent delivery systems and methods for protecting and administering active agents NEW RIVER PHARMACEUTICALS 2002-07-25 US disclosed
WO-2002034237-A1 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS NEW RIVER PHARMACEUTICALS, INC. (US) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051277-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT HDAC1 764/4885HDAC2 1668/4885CHRM1 25/4885
US-20250243161-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT HDAC1 764/4885HDAC2 1668/4885CHRM1 25/4885
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT HDAC1 764/4885HDAC2 1668/4885CHRM1 25/4885
US-20240246910-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT HDAC1 764/4885HDAC2 1668/4885CHRM1 25/4885
US-20020099013-A1 Active agent delivery systems and methods for protecting and administering active agents IAPP, CTSA, SERPINA6 HDAC1 1526/4885HDAC2 3240/4885CHRM1 3282/4885
US-20040063628-A1 Active agent delivery systems and methods for protecting and administering active agents HDGF, CTSA, IAPP HDAC1 1713/4885HDAC2 3495/4885CHRM1 2965/4885
US-12269800-B2 Delivery of therapeutic alkaloid compounds PNMT, HNMT, NNMT HDAC1 764/4885HDAC2 1668/4885CHRM1 25/4885
US-11999694-B2 Delivery of therapeutic alkaloid compounds PNMT, HNMT, NNMT HDAC1 764/4885HDAC2 1668/4885CHRM1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.